GeoVax Labs (NASDAQ:GOVX) Trading Up 1.5% – Should You Buy?

Shares of GeoVax Labs Inc. (NASDAQ:GOVX) were up 1.5% during trading on Monday . The stock traded as high as $0.68 and last traded at $0.66. Approximately 530,007 shares were traded during trading, a decline of 2% from the average daily volume of 539,257 shares. The stock had previously closed at $0.65.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GOVX shares. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of GeoVax Labs in a report on Thursday, August 7th. Wall Street Zen cut GeoVax Labs from a “hold” rating to a “sell” rating in a report on Monday, July 21st. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $8.50.

GeoVax Labs Price Performance

The firm has a market cap of $10.47 million, a price-to-earnings ratio of -0.33 and a beta of 3.57. The firm has a 50 day moving average price of $0.73 and a 200-day moving average price of $0.92.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. GeoVax Labs had a negative return on equity of 408.80% and a negative net margin of 403.88%.The business had revenue of $0.85 million for the quarter, compared to analyst estimates of $0.37 million. On average, sell-side analysts expect that GeoVax Labs Inc. will post -4.49 EPS for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds have recently added to or reduced their stakes in GOVX. Armistice Capital LLC acquired a new position in GeoVax Labs in the first quarter valued at about $703,000. Citadel Advisors LLC acquired a new position in GeoVax Labs in the fourth quarter valued at about $104,000. Jane Street Group LLC acquired a new position in GeoVax Labs in the first quarter valued at about $27,000. Finally, Northern Trust Corp acquired a new position in GeoVax Labs in the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.